Phreesia (NYSE:PHR) Given New $20.00 Price Target at Stephens

Phreesia (NYSE:PHR) had its target price decreased by equities research analysts at Stephens from $32.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ price target would indicate a potential upside of 137.56% from the stock’s current price.

A number of other equities analysts have also recently commented on the stock. BMO Capital Markets dropped their price objective on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday. Truist Financial restated a “hold” rating and issued a $11.00 price target on shares of Phreesia in a report on Tuesday. Mizuho decreased their price objective on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Barclays lowered their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, December 16th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $16.00 price objective on shares of Phreesia in a research note on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phreesia has an average rating of “Moderate Buy” and an average target price of $22.00.

Phreesia Stock Down 26.2%

Shares of NYSE:PHR opened at $8.42 on Tuesday. The firm has a market capitalization of $507.58 million, a P/E ratio of -81.54 and a beta of 0.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a 50 day moving average price of $12.51 and a 200-day moving average price of $17.68. Phreesia has a 52-week low of $8.00 and a 52-week high of $32.76.

Phreesia (NYSE:PHR) last released its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company’s revenue was up 15.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. As a group, equities research analysts anticipate that Phreesia will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling at Phreesia

In other Phreesia news, CFO Balaji Gandhi sold 3,829 shares of the company’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the sale, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at $1,652,292.40. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $36,024.72. Following the completion of the transaction, the senior vice president directly owned 157,349 shares of the company’s stock, valued at approximately $2,574,229.64. The trade was a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 70,358 shares of company stock valued at $1,123,569 in the last three months. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Federated Hermes Inc. bought a new stake in Phreesia in the 3rd quarter worth approximately $32,000. Van ECK Associates Corp grew its position in shares of Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after buying an additional 1,102 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Phreesia during the third quarter valued at approximately $45,000. Rockefeller Capital Management L.P. lifted its stake in Phreesia by 354.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock worth $47,000 after acquiring an additional 2,149 shares during the period. Finally, KBC Group NV boosted its holdings in Phreesia by 83.4% in the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after acquiring an additional 1,568 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Several brokers kept buy/outperform stances or price targets above the current level, implying upside and supporting a rebound: BMO kept an “outperform” rating with a $14 target. Benzinga
• Positive Sentiment: Canaccord Genuity reiterated a “buy” rating despite lowering its target to $22, signaling confidence in longer-term upside. Benzinga
• Positive Sentiment: Needham kept a “buy” rating while cutting its target to $14, another vote that some analysts view the stock as attractive after the pullback. Benzinga
• Neutral Sentiment: Company results: Q4 revenue of about $127M (+15.9% YoY) and fiscal-year operating/cash-flow milestones were reported, but quarter-level EPS and metric headlines were mixed across sources (some headline misses, some call transcripts indicating beats), leaving clarity for investors dependent on the call/slide details. Press Release / Slide Deck
• Negative Sentiment: Management cut FY2027 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the earlier steep share decline. Benzinga Guide Cut Article
• Negative Sentiment: Multiple analysts downgraded or cut price targets after the guidance cut — Robert W. Baird and Citigroup reaffirmed neutral/hold views with $10 targets, and Truist held at $11 — increasing near-term selling pressure and lowering consensus valuation expectations. TickerReport
• Negative Sentiment: Market reaction: headlines show shares plunged ~22–26% immediately after the results/guidance, indicating heightened short-term risk and potential for continued volatility. MSN

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.